Overview

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Status:
Completed

Trial end date:
2020-07-24

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Celgene

Treatments:

Apremilast
Thalidomide